Pharmaceutical treatment of primary open angle glaucoma

Background: Glaucoma is a progressive, irreversible optic neuropathy that results in serious vision loss and blindness. This review aimed to summarize key concepts of primary open angle glaucoma (POAG) pharmaceutical treatment trials over the last decade. Methods: We searched PubMed/MEDLINE and clinicaltrials.gov from January 1, 2010, to August 31, 2020, using the key words “POAG” and “Ocular topical therapeutics”. This search yielded 77 and 120 papers, respectively. Results: Thirty-three records were compatible with our inclusion criteria. Pharmaceutical treatment is a common intervention in POAG for lowering IOP. Prostaglandin (PG) analogues are most commonly recommended as initial medical therapy, which are administrated either as a monotherapy or in combination with other IOP-lowering classes of medications. Alternative therapies, such as ?-blockers, ?-2 adrenergic receptor agonists, and topical carbonic anhydrase inhibitors, have been used in combination or as a monotherapy. Rho-kinase inhibitors, such as netarsudil 0.02%, AR-13324 0.02%, and ripasudil are new IOP-lowering medications. Despite IOP reduction, there is a significant number of patients with POAG that may experience disease progression, and the risk of blindness over the long term is considerable. Conclusions: Clinical trials have indicated that pharmaceutical treatment of POAG is effective and safe. In addition, the new novel Rho-kinase inhibitors have shown significant IOP reduction. The new fixed combinations have also yielded significant reductions in IOP. POAG is a cause of irreversible vision loss, if not diagnosed and treated early. The condition is likely to progress in a significant number of patients, with a considerable risk of blindness in the long-term. How to cite this article: Al-Namaeh M. Pharmaceutical treatment of primary open angle glaucoma. Med Hypothesis Discov Innov Optom. 2021 Spring; 2(1): 8-17. DOI: https://doi.org/10.51329/mehdioptometry12

Parkinson's disease and convergence insufficiency: A mini-review

Background: A key manifestation of Parkinson’s disease (PD) is visual impairment. Cognitive impairment has been found to overlap with convergence insufficiency (CI) in patients with PD and is associated with significantly greater near point convergence (NPC) distance. Difficulty in reading and diplopia were the most common symptoms of CI in PD. The prevalence of CI is greater among patients with PD. Therefore, this study aimed to assess the relationship between PD and CI. Methods: Studies that had included data on CI, NPC, or both were selected by searching PubMed/MEDLINE and clinicaltrails.gov, without any timeline or language limitation. The following terms were used in PubMed/MEDLINE search: ‘Clinical Trials’, ‘Parkinson’s Disease’, and ‘Convergence Insufficiency’. For clinical trials.gov database, the terms ‘Parkinson’s Disease’, ‘Convergence Insufficiency’, and ‘Completed Studies’ were used. Only those studies with control subjects were included. PubMed/MEDLINE search yielded 1,563 articles, but no article was found in the clinical trails.gov search. Twelve articles met the inclusion criteria, among which nine articles were selected as they had data on CI or NPC distance (cm), and PD.   Results: Overall, there were 1,563 articles; among them, 12 articles met the inclusion criteria. Nine articles were selected based on their data concerning CI or NPC distance (cm) and PD. Relative to the control group, the PD group had high CI. In addition, PD group showed increase in NPC distance than the control group. Conclusions: These data suggest that the patients with PD had an increased likelihood of developing CI visual symptoms, and increased NPC distance than healthy controls. These findings indicate that regular eye examination is very important for patients with PD

Common causes of visual impairment in the elderly

Background: Aging is not a disease; rather, it is a process. As people age, visual impairment (VI) becomes more common. In 2010, the overall prevalence rate of vision impairment in all races was 25.66% in individuals aged equal to or more than 80 years, according to the estimate of the National Eye Institute at the National Institutes of Health. This review aimed to address the common causes of VI in the elderly. Methods: In this narrative review, an electronic search of the PubMed/MEDLINE database was conducted using “visual impairment” and “elderly” for the period between January 2010 and April 2021, to include randomized clinical trials and observational studies concerning VI in the elderly. The selected time period was chosen to provide an updated review. Results: The search yielded 2,955 articles published over the period of more than 11 years. The relevant randomized clinical trials or observational studies were included and reviewed. Cataracts, refractive errors, open-angle glaucoma, age-related macular degeneration, and diabetic retinopathy were the most common age-related ocular disorders leading to VI if untreated in the elderly. The loss of visual acuity can adversely affect quality of life in the elderly. Difficulty with activities of daily living related to VI can lead to social isolation, depression, and anxiety. Loss of vision in the elderly is linked to an increased risk of falls, hip fracture, depression, and poor quality of life. Conclusions: The most common causes of VI in the elderly are cataracts and refractive errors. VI in most ocular diseases is more prevalent in women than in men due to longer lifespan. The overall prevalence of the main causes of VI in the elderly is expected to increase; therefore, health policymakers should consider this when planning for the health-enhancement program of the population

Ocular manifestations of Parkinson disease

Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder. We aimed to review both the disease and the drug-related ocular manifestations of PD. Methods: In this manuscript, we have reviewed and summarized existing literature on the ocular manifestations and drug-related complications of PD. We have also discussed the use of current noninvasive imaging techniques, such as optical coherence tomography (OCT), for the early diagnosis and monitoring of PD. Results: Impaired color vision, reduced stereopsis, reduced contrast sensitivity, pupillary abnormalities, eye movement disorders, convergence insufficiency, dry eye syndrome, glaucoma, visual dysfunctions, retinal abnormalities, and drug-related side effects were among the listed ocular manifestations of PD. There is a large knowledge gap regarding the type of glaucoma affecting PD patients—whether it is open-angle or other types. Further case studies and long-term follow-ups during PD progression are necessary to fill this gap. Patient compliance with follow-up visits for more visual field tests and OCT during PD progression may become problematic when dementia and cognitive impairment occur. Conclusions: There is a general need for clinicians to perform further tests and more visual examinations to rule out ocular manifestations. Furthermore, additional clinical trials are needed to further evaluate the use of different types of OCT findings as biomarkers of PD progression. This would aid in early diagnosis and in delaying disease progression, if treated promptly

Coronavirus disease pandemic and dry eye disease: A methodology concern on the causal relationship

Letter to the edito

Effects of ascorbic acid on chemical and thermal corneal burns: A comprehensive literature review

Background: Ascorbic acid has been suggested to be effective against chemical burns. It was first tested in rabbits before being implemented in human subjects. It was proven to be useful in treatments for different conditions, such as corneal chemical and thermal burns. Herein, we aimed to review the effects of ascorbic acid in the healing of chemical and thermal corneal burns. Methods: We performed an electronic search of English literature in MEDLINE, clinicaltrials.gov, and Google Scholar, without time constraints. Articles were selected based on inclusion and exclusion criteria, using they keywords “Corneal Burn,†AND “Corneal Ulcer,†AND “Vitamin C.†This yielded 17 English language articles focused on the effect of vitamin C on chemical or thermal corneal burn-induced ulcers. Results: The 17 eligible studies that fulfilled the inclusion criteria included three retrospective, nonrandomized, comparative studies on human subjects and 14 in vivo, laboratory-based studies on rabbits (12 studies), rats (one study), as well as guinea-pigs (one study). Most studies showed benefits in using vitamin C as a prophylactic treatment to delay or stop corneal ulcer formation after chemical or thermal corneal burn. Conclusions: Vitamin C is a very basic, inexpensive prescription and can be used to treat corneal ulcers following a variety of corneal burns. This review highlights the necessity for conducting randomized controlled trials to investigate the prophylactic role of vitamin C and to determine its minimum required dose for the management of corneal ulcers after different types of corneal burns

COVID-19 and conjunctivitis: a meta-analysis

Abstract COVID-19 is a disease first identified in Wuhan City, Hubei Province, China, in December 2019, causes by a SARS-COV-2 virus infection. By 27 October 2020, 43,921,473 confirmed cases were reported worldwide, with 1,166,389 COVID-19 deaths. Conjunctivitis has been reported in adults and pediatric patients with COVID-19. Objective: The aim of this meta-analysis is to estimate the odd Ratio (ORs) of conjunctivitis in patients with COVID-19. Methods: A systematic review and meta-analysis have been performed using the PubMed and Google Scholar literature search. The ORs of conjunctivitis in adults and pediatric patients is the outcome of this meta-analysis. Results: There have been 1041 articles published since the outbreak in December 2019, according to the latest literature. For the meta-analysis, 20 studies with a total of 3383 participants were included. The odds ratio (ORs) of conjunctivitis was 0.01 (95% confidence interval [CI]: 0.00–0.02). No bias has been reported. Conclusion: Conjunctivitis is the most common ocular manifestations reported in adults. This comprehensive meta-analysis quantifies the existing evidence linking conjunctivitis with COVID-19 and highlights the high percentage of heterogeneity that is shown in the current studies. Finally, it offers a single review article which includes all the current articles available for COVID-19 and conjunctivitis in adults and children

A systematic review of the effect of omega-3 supplements on meibomian gland dysfunction

Introduction: Meibomian gland dysfunction (MGD) is the leading cause of dry eye syndrome (DES). Many ocular disorders including DES and blepharitis can be linked to MGD. If we treat MGD, we can treat related diseases easily. Purpose: This systematic review is intended to determine the efficacy of omega-3 supplementation in MGD patients. Methods: This systematic review included an electronic search on PubMed and Clinicaltrials.gov to include all randomized clinical trials (RCTs) using omega-3 as a treatment for MGD. Results: Database search yielded to one RCT and six clinical trials through the MEDLINE of a total of 350 participants for the systematic review and meta-analysis study. The investigated treatment group (omega-3 group) had a positive effect on MGD protection in the invasive sodium fluorescein-tear break up time (NaFl-TBUT) score compared with the placebo group (odd ratio = 8.72, 95% confidence interval: 4.73, 16.09; p < 0.001). These data suggest that the odd ratios of the omega-3 group to control group increased the likelihood of the improved stated outcome tear break up time (TBUT) being achieved in the treatment group. No evidence of publication bias was detected in the funnel plot inspection or the Egger’s statistical test (p = 0.2944). Conclusions: A moderate daily dose of omega-3 may be a beneficial therapeutic for MGD. Omega-3 has been beneficial in many diseases, such as heart attack prevention and agerelated macular degeneration, and this systematic review emphasizes its protection against MGD. In addition, this review emphasizes the precision of noninvasive TBUT (NITBUT) compared with invasive NaFl-TBUT which may suggest the importance of NITBUT in the clinic

Vision Loss Among Delaware Nursing Home Residents

Objectives: To determine the prevalence of vision loss among Delaware nursing home residents for further data collection to expand the existing evidence about the vision loss among nursing home residents on a national level. Methods: This cross-sectional study involved the statistical analysis of comprehensive eye examination records of 1,856 nursing residents residing in 20 Delaware nursing homes from 2005 to 2011. Descriptive statistical analyses were conducted to identify age-specific prevalence rates of vision loss (moderate-to-severe vision impairment and blindness). Results: The mean age of nursing home residents was 82.54 years (range: 65–111 years), and 61.70% were over the age of 80 years. The majority of nursing home residents were female (64.10%) and White (76.30%). The overall prevalence rates of moderate-to-severe vision impairment and blindness were 47.40% and 16.20%, respectively. Discussion: The high prevalence of vision loss among Delaware Nursing home residents indicates a demand for further data collection for expanding the existing evidence about the vision loss among nursing home residents on a national level

Vision Loss Among Delaware Nursing Home Residents

Objectives: To determine the prevalence of vision loss among Delaware nursing home residents for further data collection to expand the existing evidence about the vision loss among nursing home residents on a national level. Methods: This cross-sectional study involved the statistical analysis of comprehensive eye examination records of 1,856 nursing residents residing in 20 Delaware nursing homes from 2005 to 2011. Descriptive statistical analyses were conducted to identify age-specific prevalence rates of vision loss (moderate-to-severe vision impairment and blindness). Results: The mean age of nursing home residents was 82.54 years (range: 65-111 years), and 61.70% were over the age of 80 years. The majority of nursing home residents were female (64.10%) and White (76.30%). The overall prevalence rates of moderate-to-severe vision impairment and blindness were 47.40% and 16.20%, respectively. Discussion: The high prevalence of vision loss among Delaware Nursing home residents indicates a demand for further data collection for expanding the existing evidence about the vision loss among nursing home residents on a national level